

DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: USE OF 5,10-METHYLENE TETRAHYDROFOLATE FOR THE TREATMENT OF CANCER the specification of which was filed on Int'l Filing Date April 1, 2005 as Int'l Application No. PCT/US2005/011046, U.S. Application No. 10/594,850.

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)



Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
WIPO	PCT/US2005/011046	April 1, 2005	Yes

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
60/558,889	April 2, 2004	Lapsed
60/625,479	November 4, 2004	Lapsed
60/658,745	March 4, 2005	Lapsed

Full Name of Inventor 1:	Last Name: ROBBINS	Suffix:	First Name: JOAN	Middle Name or Initial: M.
Residence & Citizenship:	City: San Diego		State/Foreign Country: California	Country of Citizenship: United States
Post Office Address:	Post Office Address: 10710 Edenoaks St.,		City: San Diego	State/Country: California Postal Code: 92131
Full Name of Inventor 2:	Last Name: CANTWELL	Suffix:	First Name: MARK	Middle Name or Initial: J.
Residence & Citizenship:	City: San Diego		State/Foreign Country: California	Country of Citizenship: United States
Post Office Address:	Post Office Address: 11525 Caminito La Bar, #50		City: San Diego	State/Country: California Postal Code: 92126

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Joan M. ROBBINS Date: June 12, 2007	Signature of Inventor 2  Mark J. CANTWELL Date: June 12, 2007
--	--

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)Joan M. ROBBINS and Mark J.
CANTWELLAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No**2. Name and address of receiving party(ies)**Name: Adventrx Pharmaceuticals, Inc.

Internal Address: _____

Street Address: 6725 Mesa Ridge Rd., Suite 100City: San DiegoState: CACountry: US Zip: 92121Additional name(s) & address(es) attached? ☐ Yes ☒ No**3. Nature of conveyance/Execution Date(s):**Execution Date(s) June 12, 2007☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Joint Research Agreement☐ Government Interest Assignment☐ Executive Order 9424, Confirmatory License☐ Other _____**4. Application or patent number(s):**☐ This document is being filed together with a new application.

A. Patent Application No.(s)

10/594,850

B. Patent No.(s)

06/25/2007 MKAYPAGH 00000109 201430 10594850

02 FC:8021 40.00 DA

Additional numbers attached? ☐ Yes ☒ No**5. Name and address to whom correspondence concerning document should be mailed:**Name: Kenneth A. Weber

Internal Address: _____

TOWNSEND AND TOWNSEND AND CREW LLPStreet Address: Two Embarcadero Center,
Eighth FloorCity: San FranciscoState: California Zip: 94111-3834Phone Number: (415) 576-0200Fax Number: (415) 576-0300Email Address: kaw@townsend.com**6. Total number of applications and patents involved:** 1**7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00**☐ Authorized to be charged by credit card☒ Authorized to be charged to deposit account☐ Enclosed☐ None required (government interest not affecting title)**8. Payment Information**

a. Credit Card Last 4 numbers _____

Expiration Date _____

b. Deposit Account Number 20-1430Authorized User Name Townsend andTownsend and Crew LLP**9. Signature:**

Signature

June 20, 2007

Date

Kenneth A. Weber

Name of Person Signing

Atty. Reg. No. 31,677

Total number of pages including cover
sheet, attachments, and documents:

2

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, VA 22313-1450

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, Joan ROBBINS of 10710 Edenoaks St., San Diego, CA 92131; and Mark CANTWELL of 11525 Caminito La Bar, #50, San Diego, CA 92126, hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: USE OF 5,10-METHYLENE TETRAHYDROFOLATE FOR THE TREATMENT OF CANCER

Int'l Appln No.: PCT/US2005/011046

Int'l Filing Date: April 1, 2005

U.S. Application No.: 10/594,850; and


WHEREAS, Adventrx Pharmaceuticals, Inc., a corporation of Delaware, located at 6725 Mesa Ridge Rd., Suite 100, San Diego, CA 92121, hereinafter referred to as "Assignee," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: June 12, 2005


JOAN ROBBINS

Dated: June 12, 2005


MARK CANTWELL